ProSci-Inc’s RIP3/RIPK3 antibody (Cat. No. PSI-2283) is widely cited with as many as 171 citations on CiteAb and 165 citations on Bioz.
My Cites are Set on You!
Deliver Functional Proteins and Antibodies into Living Cells
OZ Biosciences offers solutions to deliver functional Proteins and Antibodies into living cells.
Immune Checkpoints
ProSci offers reagents that can be used to study the actions of multiple immune checkpoint proteins such as CTLA-4, PD-1, & its ligands PD-L1 & PD-L2.
Viral Infectious Diseases
To support research & studies into infectious diseases, ProSci has reagents for the study of many viral disease agents inc. Covid, HIV, & Influenza.
The Role of Monoclonal Antibodies & Biosimilars in Life Science Research
mAbs (biosimilars) as tools to research novel new therapies and uncover effective off-target application.
Insights into the Molecular Mechanisms Regulating Necroptosis
This white paper details findings in molecular mechanisms that govern necroptosis related to RIPK & details #2283 use to analyse expression of RIPK3.
Exploring the Roles of RIPKs in Immune Responses, Inflammation, and Cell Death: Recent Findings
ProSci has 25+ years expertise in developing antibodies. This white paper details use of RIPK antibodies & findings on RIPKs in signalling pathways.
A Deep Dive into the Hidden Power of Programmed Cell Death: Unlocking Therapeutic Potential with Antibodies
ProSci has 25+ years of expertise in developing antibodies. This white paper details use of ProSci antibodies in the study of programmed cell death.
PD-1: Expanding Beyond Cancer Research
ProSci details the importance of PD-1 antibodies are important in resolving complex interactions between the immune system & pathological conditions.
HVEM – BTLA – LIGHT – CD160 Network
The checkpoint receptors/ligands system HVEM, LIGHT, CD160 and BTLA (CD272) is part of a complex network of overlapping receptor interactions.